Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
201 studies found for:    vaccinia virus
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Genetic: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
2 Completed Safety Study of Modified Vaccinia Virus to Cancer
Conditions: Melanoma;   Breast Cancer;   Head and Neck Squamous Cell Cancer;   Liver Cancer;   Colorectal Cancer;   Pancreatic Adenocarcinoma
Intervention: Biological: Vaccinia virus (vvDD-CDSR)
3 Completed Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox
Condition: Healthy
Intervention: Drug: Modified Vaccinia Virus Ankara TBC-MVA
4 Completed Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
Condition: Carcinoma, Colorectal
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
5 Completed Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
Conditions: Melanoma;   Lung Cancer;   Renal Cell Carcinoma;   Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
6 Completed A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
Condition: Neoplasms, Liver
Intervention: Genetic: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
7 Completed Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma
Condition: Melanoma
Interventions: Genetic: Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes;   Biological: Intranodal booster immunizations with synthetic melanoma associated epitopes
8 Terminated Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors
Condition: Colorectal Carcinoma
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
9 Completed Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Conditions: Neuroblastoma;   Rhabdomyosarcoma;   Lymphoma;   Wilm's Tumor;   Ewing's Sarcoma
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
10 Completed A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
Condition: Melanoma
Intervention: Biological: JX-594
11 Withdrawn Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection
Conditions: Healthy;   Communicable Diseases
Intervention: Drug: Vaccinia Immune Globulin (Human)
12 Enrolling by invitation VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
Condition: Complication of Smallpox Vaccination
Intervention: Biological: VIGIV
13 Completed Phase I Trial of Smallpox Vaccine
Condition: Healthy
Intervention: Drug: Modified Vaccinia Virus Ankara TBC-M
14 Completed A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
Condition: Peritoneal Carcinomatosis
Intervention: Biological: GL-ONC1
15 Withdrawn Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin
Condition: Ovarian Cancer
Intervention: Biological: JX-594
16 Completed Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
Condition: Cancer of Head and Neck
Intervention: Biological: GL-ONC1
17 Terminated Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: recombinant vaccinia-MUC1 vaccine;   Biological: recombinant vaccinia-TRICOM vaccine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
18 Completed Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
Conditions: Colorectal Carcinoma;   CRC
Interventions: Biological: JX-594;   Drug: Irinotecan
19 Completed Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults
Condition: HIV Infections
Interventions: Biological: pGA2/JS7 DNA;   Biological: Modified vaccinia Ankara/HIV62
20 Recruiting Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Condition: Hepatocellular Carcinoma (HCC)
Interventions: Biological: Pexastimogene Devacirepvec (Pexa Vec);   Drug: Sorafenib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.